Navigation Links
Senesco Chooses VGXI to Produce Factor 5A Plasmid
Date:7/3/2008

NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to supply the plasmid portion of the Company's combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.

Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid against subcutaneous multiple myeloma tumors in immunodeficient mice. The Factor 5A plasmid being produced by VGXI, as Senesco's preclinical data has shown, should cause cancer cells to enter apoptosis, or programmed cell death.

"VGXI's manufacturing and technical expertise in producing plasmids for Senesco's planned toxicology study and ultimately our clinical trial led us to choose them. We are pleased to be working with a company that has such an outstanding reputation in the field," commented Bruce Galton, Senesco's President and CEO.

Henry Hebel, Vice President of Operations for VGXI said, "We believe that our ability to quickly supply the preclinical and clinical needs of our clients will allow Senesco to rapidly advance their programs. We are continuing to expand our collaborative development services to meet the growing needs for a wide variety of plasmid based products."

About VGXI Inc.

VGXI Inc. is a leading manufacturer of DNA plasmids, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI offers a wide variety of contract manufacturing services to outside client organizations. The Company's cGMP manufacturing facility in The Woodlands, Texas is a flexible, purpose-built facility used for research,
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
2. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
3. Senesco Technologies Initiates Preclinical Studies for Cancer Target
4. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
5. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
6. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
7. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
8. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
11. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported pro ... months ended March 31, 2015 compared to a pro ... same period in 2014.  Isis, significantly improved financial results ... from its partners compared to the same quarter last ... from operations of $9.3 million for the three months ...
(Date:5/5/2015)...  Accuray Incorporated (Nasdaq: ARAY ), announced today that ... America Merrill Lynch 2015 Healthcare Conference in ... at 2:20pm PT.   A live webcast ... Relations page of the Company,s website at http://www.accuray.com/investors ... approximately one hour after the conclusion of the live ...
(Date:5/5/2015)... May 5, 2015  Kewaunee Scientific Corporation (NASDAQ: KEQU ... to Kewaunee Scientific,s Board of Directors, effective April 29, ... North Carolina . The election of Mr. ... notification to the Board of his intention to resign from ... professional commitments. Upon his election, Mr. Gehl was also elected ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 13Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 2Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 3
... for Clinical Trial of ALXN6000 in Cancer, ... ALXN ) today announced that the U.S. ... titled,"Polypeptides and Antibodies Derived from Chronic Lymphocytic Leukemia,Cells ... Alexion and includes,claims that encompass the composition-of-matter of ...
... Broad New Patent Granted, CAMBRIDGE, Mass. and CARLSBAD, ... and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ),today announced ... mipomersen in,patients with heterozygous familial hypercholesterolemia (heFH), a genetic,disorder ... is,the first of four new trials the companies plan ...
Cached Medicine Technology:Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 2Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 3Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 4Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 2Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 3Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 4Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 5Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 6Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 7
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host ... about alternatives for youngsters to do this summer. As the ... idea for starting a summer camp and how is it ... called Once Upon a Party and I come to children’s ... even scripture. We play games, sing, and dance and have ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 For the growing ... HiTemp140 series of data loggers. This data logger ... the electronic components for optimum performance throughout exposure to high ... data loggers are capable of storing up to 32,700 ... battery life of one year or longer. All data loggers ...
(Date:5/5/2015)... May 05, 2015 In the upbeat Moms ... is for moms to support each other. Parenting is ... other’s side makes it so much easier. Mothers talk ... better, feel less alone and help them realize there’s no ... Moms who are clearly dear friends share that it's ...
(Date:5/5/2015)... Buckeye Health Plan (BHP) is pleased to ... president of Buckeye Health Plan. Hill, known for growing ... Hill has more than 28 years of healthcare leadership ... managed care to large health care provider systems. Most ... of Michigan, a health plan serving the Medicaid, Medicare ...
(Date:5/5/2015)... KNOXVILLE, Tenn. (PRWEB) May 05, 2015 ... company that provides innovative interoperability solutions for hospitals ... ROI cost savings calculator. Hospital CIOs and CTOs ... at healthslide.com. The calculator shows both initial and ... offering, Boomerang. , “Our nation’s hospitals pay ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:HealthSlide Launches ROI Cost Calculator 2
... 26 Pregis Corporation, a leading international manufacturer, marketer, ... solutions, today announced its 2008 fourth quarter and full ... Company generated net sales of $219.6 million, a decrease ... the fourth quarter of 2007. Excluding incremental revenue ...
... March 26 Abusing real-time communication tools like instant ... of sales reps to engage with physicians."A lot of ... more efficient," stated a sales executive in a roundtable ... "In reality, they,re so distracted by doing four things ...
... suppresses enzyme vital to tumor growth , , THURSDAY, March 26 ... also help slow the spread of a deadly type of ... published in the current issue of the International Journal ... telomerase. Telomerase activity appears to be essential for certain tumor ...
... PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, Australia, ... ), a leader in device-based mechanical circulatory support therapies ... International, Inc. (Nasdaq: HTWR ; ASX: HIN), ... today that they each received a Request for Additional ...
... Patient Health and Safety and Pharmaceutical Innovation ... Generic Pharmaceutical Association (GPhA) released the following ... Kathleen Jaeger regarding the bipartisan Senate introduction ... Life-Saving Medicine Act.""Momentum is skyrocketing for biogenerics ...
... Safeguard and Comerica Debt Facilities; Support Robust GrowthALISO VIEJO, ... CLRT ), a premier anatomic pathology and ... pharmaceutical industry, announced today that it has entered into ... Oak Investment Partners , a multi-stage venture capital ...
Cached Medicine News:Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:Sales Force Effectiveness: Less Texting, More Engagement 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 3Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 4Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 5Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 3Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 4Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 5Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 6Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 7Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 8
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
... provides leading edge information ... involving all aspects of ... on diagnosis and management ... venous disease. CVMstat® reviews ...
A Practical Approach to TEE puts detailed "how-to" information on transesophageal echocardiography (TEE) at the clinician's fingertips in the operating room, intensive care unit, office, or any other...
Medicine Products: